Merck Closes $1.1B Sirna Acquisition After RNAi Shop Tentatively Settles Three Lawsuits
January 04, 2007
Merck Closes $1.1B Sirna Acquisition After RNAi Shop Tentatively Settles Three Lawsuits
The firms closed the deal after Sirna was able to tentatively settle a trio of shareholder-led lawsuits seeking to block the acquisition. The suits accused Sirna brass of double-dealing in their negotiations with Merck.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UniQure, Collaborators Secure $3.2M Eurostar Grant for Huntington’s Disease Effort
May 23, 2013 / Gene Silencing News - NIH Awards $400K to Fund Three microRNA Research Grants in May
May 23, 2013 / Gene Silencing News - Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug
May 23, 2013 / Gene Silencing News - MiRagen Hits First Milestone in Servier microRNA Drug Partnership
May 23, 2013 / Gene Silencing News - Cenix to Provide Research Services to Debiopharm
May 23, 2013 / Gene Silencing News